Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

Daniel L. Hertz(GTx (United States)), Howard L. McLeod(Unknown), Stefanie D. Krens(University of North Carolina at Chapel Hill), Michael J. Morris(Dana-Farber Cancer Institute), Jai N. Patel(Levine Cancer Institute), Ivo Shterev(Statistical and Applied Mathematical Sciences Institute), Yoichi Furukawa(The University of Tokyo), Alexander B. Sibley(Duke University), Cameron Lassiter(University of Maryland, Baltimore), Cynthia L. Renn(University of Maryland, Baltimore), Kouros Owzar(Duke University), Michael J. Kelley(Durham VA Health Care System), Sherrie Lessans(University of Maryland, Baltimore), Flora Mulkey(Sherwin Williams (United States)), Susan Halabi(Duke Medical Center), Deanna L. Kroetz(University of California, San Francisco), M. Eileen Dolan(National Institutes of Health), Phillip G. Febbo(Veracyte (United States)), Heather E. Wheeler(Loyola University Chicago), Claudia Wing(University of Chicago), Mark J. Ratain(University of Chicago), Michiaki Kubo(RIKEN Center for Integrative Medical Sciences), Lois S. Weisman(University of Michigan), Susan G. Dorsey(University of Maryland, Baltimore), Chen Jiang, Yusuke Nakamura(National Institute of Biomedical Innovation, Health and Nutrition), John F. Mahoney(University of Pittsburgh), Dorothy Watson(University of North Carolina at Chapel Hill), William Kevin Kelly(Thomas Jefferson University), Michael A. Carducci(Sidney Kimmel Comprehensive Cancer Center), Paula N. Friedman(University of North Carolina at Chapel Hill), Eric J. Small(CancerCare Manitoba)
Clinical Cancer Research
May 3, 2016
Cited by 57


Related Papers